ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BioMarin sells another review voucher

by Lisa M. Jarvis
December 4, 2017 | APPEARED IN VOLUME 95, ISSUE 48

BioMarin Pharmaceutical has sold a second rare-pediatric-disease priority review voucher (PRV), this time for $125 million. BioMarin earned the voucher in April when the U.S. Food & Drug Administration approved Brineura, a treatment for kids with a form of Batten disease. The voucher allows the undisclosed buyer to trim four months off FDA’s review time for a New Drug Application. In 2014, BioMarin raked in $67.5 million for a voucher it received alongside the approval of Vimizim, a treatment for Morquio syndrome A. Rare-pediatric-disease PRVs were introduced in 2012 as an incentive to spur investment in diseases with few or no treatment options.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment